<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02579252</url>
  </required_header>
  <id_info>
    <org_study_id>AC-AD-003</org_study_id>
    <secondary_id>2015-000630-30</secondary_id>
    <nct_id>NCT02579252</nct_id>
  </id_info>
  <brief_title>24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease</brief_title>
  <acronym>ADAMANT</acronym>
  <official_title>A 24 Months Randomised, Placebo-controlled, Parallel Group, Double Blinded, Multi Centre, Phase 2 Study to Assess Safety and Efficacy of AADvac1 Applied to Patients With Mild Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Axon Neuroscience SE</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Axon Neuroscience SE</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety and efficacy of AADvac1 in the treatment of patients with
      mild Alzheimer's disease.

      60% of participants will receive AADvac1 and 40% of participants will receive placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alzheimer's disease (AD) is a chronic progressive neurodegenerative disorder of the brain.
      Over the course of the disease, pathological proteins accumulate in the brain, damaging
      neurons, thus causing them to lose their connections and die.

      Currently available treatments are designed to compensate for the neurotransmitter loss
      caused by the disease without affecting the disease process itself.

      AADvac1 is designed to raise antibodies against pathological tau protein (the primary
      constituent of neurofibrillary pathology in AD). These antibodies are expected to prevent tau
      protein from aggregating, to facilitate the removal of tau protein aggregates and prevent the
      spreading of pathology, slowing or halting the progress of the disease.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (all-case treatment-emergent adverse events except local reactions)</measure>
    <time_frame>24 months</time_frame>
    <description>The safety and tolerability of AADvac1 in the treatment of patients with mild Alzheimer disease, as assessed by AEs, vital signs, ECG, laboratory measures, MRI of the brain, physical and neurological examination, Columbia Suicide Severity Rating Scale (C-SSRS) and review of the Patient Diary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Dementia Rating (CDR) Sum of Boxes</measure>
    <time_frame>24 months</time_frame>
    <description>The domain scores of the standard 6-domain CDR assessment will be summed up to obtain a Sum-of-Boxes score of 0-18</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Custom cognitive battery (composite standard score)</measure>
    <time_frame>24 months</time_frame>
    <description>A composite standard score will be calculated from the following tests:
Cogstate International Shopping List Task (memory)
immediate free recall
delayed free recall
delayed recognition
Cogstate One Card Learning Task (memory)
Cogstate One Card Back Task (memory)
Category Fluency Test (executive function, language)
Letter Fluency Test (executive function, language)
Digit Symbol Coding (executive functioning, working memory and processing speed)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alzheimer's Disease Cooperative Study - Activities of Daily Living questionnaire (version for Mild Cognitive Impairment) (ADCS MCI ADL)</measure>
    <time_frame>24 months</time_frame>
    <description>Activities of daily living will be assessed using the informant-based ADCS questionnaire (both the score for the 18-point and the 24-point version will be calculated)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory: Fludeoxyglucose Positron Emission Tomography (FDG PET) assessment of brain metabolism (change in cerebral glucose metabolic rate expressed as Standardised Uptake Value Ratio [SUVR] change, multiple regions of interest)</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory: MRI volumetry</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory: Cerebrospinal fluid (CSF) biomarkers</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">208</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>AADvac1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AADvac1 is a suspension for subcutaneous injection. AADvac1 is provided in single-use vials. Dosage: 40 µg Axon peptide 108 (coupled to keyhole limpet haemocyanin (KLH)) using aluminium hydroxide (containing 0.5 mg Al3+) as adjuvant, in a phosphate buffer.
Patients receive 6 doses in 4-week intervals, and then 5 individual booster doses in 3-month intervals, for a total of 11 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo is a suspension for subcutaneous injection. Placebo is provided in single-use vials. Dosage: aluminium hydroxide (containing 0.5 mg Al3+), in a phosphate buffer. Patients receive 6 doses in 4-week intervals, and then 5 individual booster doses in 3-month intervals, for a total of 11 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AADvac1</intervention_name>
    <arm_group_label>AADvac1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria (abbreviated):

          -  Diagnosis of probable Alzheimer's disease according to the revised National Institute
             on Aging-Alzheimer's Association (NIA-AA) criteria (McKhann 2011).

          -  Mini Mental State Examination (MMSE) score ≥ 20 and ≤ 26.

          -  Brain MRI finding consistent with the diagnosis of Alzheimer's disease

          -  Medial temporal lobe atrophy: Scheltens score of ≥ 2 (on a scale of 0-4 on the more
             atrophied side) AND/OR positive AD biomarker profile in the CSF (amyloid+, tau+)

          -  At least 6 years of formal elementary education.

          -  Age 50-85 years.

          -  Fluency in the local language and sufficient auditory and visual capacities to allow
             neuropsychological testing.

          -  Ability to read and understand the informed consent.

          -  Stable therapy with an acetylcholinesterase inhibitor for at least 3 months prior to
             screening.

          -  If the patient is on memantine treatment, the dose regimen must be stable for at least
             3 months prior to screening.

          -  Hachinski Ischemia Scale score ≤ 4.

          -  Availability of a caregiver.

          -  Female patients must be either surgically sterile or at least 2 years postmenopausal.

          -  Male patients must either be surgically sterile, or he and his female spouse/partner
             who is of childbearing potential must be using highly effective contraception starting
             at screening and continuing throughout the study period.

          -  Patient provides written informed consent.

        Exclusion criteria (abbreviated):

          -  Participation in another clinical study within 3 months prior to screening.

          -  Pregnant or breastfeeding female.

          -  Not expected to complete the clinical study.

          -  Known allergy to components of the vaccine.

          -  Contraindication for MRI imaging.

          -  Any of the following detected by brain MRI:

               -  Infarction in the territory of large vessels

               -  More than one lacunar infarct.

               -  Any lacunar infarct in a strategically important location.

               -  Confluent hemispheric deep white matter lesions (Fazekas grade 3).

               -  Other focal lesions which may be responsible for the cognitive status of the
                  patient or any other abnormalities associated with significant central nervous
                  disease other than Alzheimer's disease.

          -  Surgery (under general anaesthesia) within 3 months prior to screening and/or
             scheduled surgery (under general anaesthesia) during the whole study period.

          -  Patient has a history and/or currently suffers from a clinically significant
             autoimmune disease, or is expected to receive immunosuppressive or immunomodulatory
             treatment at the present or in the future.

          -  Recent history of cancer (last specific treatment ≤ 5 years prior to Screening).

          -  Myocardial infarction within 2 years prior to screening.

          -  Hepatitis B, C, HIV or Syphilis.

          -  Active infectious disease.

          -  Presence and/or history of immunodeficiency.

          -  Patient currently suffering from a clinically important systemic illness:

               -  poorly controlled congestive heart failure (NYHA ≥ 3)

               -  BMI &gt; 40

               -  poorly controlled diabetes (HbA1c &gt; 7.5%)

               -  severe renal insufficiency (eGFR &lt; 30 mL/min)

               -  chronic liver disease - ALT (alanine aminotransferase) &gt; 66 U/L in females or &gt;
                  80 U/L in males, AST (aspartate aminotransferase) &gt; 82 U/L

               -  QTc interval prolongation in ECG (&gt; 450 ms)

               -  other clinically significant systemic illness, if considered relevant by the
                  investigator

          -  Hypothyroidism, defined as TSH (thyroid-stimulating hormone) elevation &gt; 5.000
             mcIU/mL, and/or FT4 levels &lt; 0.7 ng/dL. Patients with corrected hypothyroidism are
             eligible for the study provided that treatment has been stable for 3 months before
             study entry.

          -  Valid diagnosis of a significant psychiatric illness such as schizophrenia, any type
             of psychotic disorder or bipolar affective disorder.

          -  Current depressive episode (Geriatric Depression Scale GDS ≥ 6) or major depressive
             episode within the last 1 years.

          -  Metabolic or toxic encephalopathy or dementia due to a general medical condition.

          -  History of alcohol or drug abuse or dependence within the past 2 years.

          -  Wernicke's encephalopathy.

          -  History or evidence of any CNS disorder other than AD that could be the cause of
             dementia.

          -  Cerebrovascular disease (ischemic or haemorrhagic stroke), or diagnosis of possible,
             probable or definite vascular dementia.

          -  Epilepsy.

          -  Treatment with experimental immunotherapeutics including intravenous immunoglobulin
             within 3 months prior to screening.

          -  Treatment with experimental therapies for AD aiming at disease-modification within 3
             months prior to screening.

          -  Patient is currently being treated or was treated in the past with any active vaccines
             for AD.

          -  Treatment with immunosuppressive drugs.

          -  Change in dose of previous and current medications within the last 30 days prior to
             Screening (V01), if considered clinically relevant by the investigator.

          -  Vitamin B12 deficiency (serum vitamin B12 &lt; 191 pg/mL).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reinhold Schmidt, Prof. MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University, Graz, Austria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ordination Dr. Bancher</name>
      <address>
        <city>Horn</city>
        <state>Niederosterreich</state>
        <zip>3580</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Neurologie</name>
      <address>
        <city>Graz</city>
        <state>Steiermark</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abteilung Psychiatrie und Psychotherapie, LKH Hall</name>
      <address>
        <city>Hall in Tirol</city>
        <state>Tirol</state>
        <zip>6060</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <state>Tirol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice u sv. Anny v Brne, Mezinarodni centrum klinickeho vyzkumu (ICRC), Centrum pro kognitivni poruchy, Neuro 2</name>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Hradec Kralove, Neurologicka Klinika</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Narodni ustav dusevniho zdravi (NÚDZ), Department of cognitive disorders - AD Center</name>
      <address>
        <city>Klecany</city>
        <zip>250 67</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze</name>
      <address>
        <city>Praha</city>
        <zip>128 21</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice v Motole</name>
      <address>
        <city>Praha</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuro Centrum Odenwald</name>
      <address>
        <city>Erbach</city>
        <state>Rheinland-Pfalz</state>
        <zip>64711</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arzneimittelforschung Leipzig (AFL)</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04107</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Heidelberg, Zentralinstitut für Seelische Gesundheit</name>
      <address>
        <city>Mannheim</city>
        <zip>68159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der Technischen Universität München, Klinik und Poliklinik fur Psychiatrie und Psychotherapie</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Klaus Christian Steinwachs</name>
      <address>
        <city>Nürnberg</city>
        <zip>90402</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm, Klinik und Poliklinik für Neurologie</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Podlaskie Centrum Psychogeriatrii</name>
      <address>
        <city>Bialystok</city>
        <zip>15-756</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pallmed prowadzacy NZOZ Dom Sue Ryder w Bydgoszczy Centrum Psychoneurologii Wieku Podeszlego</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-796</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wielospecjalistyczna Poradnia Lekarska Synapsis</name>
      <address>
        <city>Katowice</city>
        <zip>40-123</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Care Clinic</name>
      <address>
        <city>Katowice</city>
        <zip>40-752</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Neurologii Klinicznej, Krakowska Akademia Neurologii</name>
      <address>
        <city>Kraków</city>
        <zip>31-505</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KO-MED Centra Kliniczne Sp. z o.o.</name>
      <address>
        <city>Lublin</city>
        <zip>20-362</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oddzial Neurologiczny</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-082</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Neuro-Kard</name>
      <address>
        <city>Poznan</city>
        <zip>61-853</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EUROMEDIS Sp. z o.o.</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne NeuroProtect</name>
      <address>
        <city>Warszawa</city>
        <zip>﻿01-697</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wrocławskie Centrum Alzheimerowskie</name>
      <address>
        <city>Wroclaw</city>
        <zip>53-139</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Dr. Constantin Gorgos&quot; Psychiatry Hospital Titan</name>
      <address>
        <city>Bucharest</city>
        <zip>﻿030447</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologicka ambulancia</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>974 04</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nestatna psychiatricka ambulancia</name>
      <address>
        <city>Bratislava</city>
        <zip>81107</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univerzitna nemocnica Bratislava, Nemocnica Stare Mesto, I. Neurologicka klinika LF UK a UNB</name>
      <address>
        <city>Bratislava</city>
        <zip>813 69</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univerzitna nemocnica Bratislava, Psychiatricka klinika LFUK a UNB</name>
      <address>
        <city>Bratislava</city>
        <zip>81369</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univerzitna nemocnica L Pasteura Kosice, Psychiatricka klinika</name>
      <address>
        <city>Kosice</city>
        <zip>﻿041 90</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NEURES, s.r.o. Neurologicka ambulancia</name>
      <address>
        <city>Krompachy</city>
        <zip>﻿05342</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum zdravia R.B.K., s.r.o., Psychiatricka ambulancia</name>
      <address>
        <city>Svidnik</city>
        <zip>﻿089 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pro Mente Sana S.R.O., Psychiatricka Ambulancia</name>
      <address>
        <city>Trencin</city>
        <zip>91108</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultna nemocnica s poliklinikou Zilina, Psychiatricke oddelenie</name>
      <address>
        <city>Zilina</city>
        <zip>﻿012 07</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univerzitetni klinični Center Ljubljana, Neurology Clinic</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Centre Maribor</name>
      <address>
        <city>Maribor</city>
        <zip>2000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skånes Universitetssjukhus Malmö, Minneskliniken</name>
      <address>
        <city>Malmö</city>
        <zip>SE-20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukhuset, Minnesmottagningen</name>
      <address>
        <city>Mölndal</city>
        <zip>SE-43141</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset Huddinge</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademiska Sjukhuset I Uppsala, Minnes-och geriatrikmottagningen</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
    <country>Sweden</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <reference>
    <citation>Kontsekova E, Zilka N, Kovacech B, Skrabana R, Novak M. Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's disease. Alzheimers Res Ther. 2014 Aug 1;6(4):45. doi: 10.1186/alzrt277. eCollection 2014.</citation>
    <PMID>25478018</PMID>
  </reference>
  <reference>
    <citation>Kontsekova E, Zilka N, Kovacech B, Novak P, Novak M. First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model. Alzheimers Res Ther. 2014 Aug 1;6(4):44. doi: 10.1186/alzrt278. eCollection 2014.</citation>
    <PMID>25478017</PMID>
  </reference>
  <reference>
    <citation>Novak P, Schmidt R, Kontsekova E, Zilka N, Kovacech B, Skrabana R, Vince-Kazmerova Z, Katina S, Fialova L, Prcina M, Parrak V, Dal-Bianco P, Brunner M, Staffen W, Rainer M, Ondrus M, Ropele S, Smisek M, Sivak R, Winblad B, Novak M. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol. 2017 Feb;16(2):123-134. doi: 10.1016/S1474-4422(16)30331-3. Epub 2016 Dec 10.</citation>
    <PMID>27955995</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2015</study_first_submitted>
  <study_first_submitted_qc>October 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2015</study_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaccine</keyword>
  <keyword>tau protein</keyword>
  <keyword>active</keyword>
  <keyword>immunization</keyword>
  <keyword>KLH</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>tau</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aluminum Hydroxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

